Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection

Pediatric Transplantation

Volumn 9, Issue 2, 2005, Pages 155-161

  Jordan, Stanley C ^a,b,c   Vo, Ashley A ^a   Toyoda, Mieko ^a   Tyan, Dolly ^a   Nast, Cynthia C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pediat Nephrol/Transplant Immunol ^*  (United States)

^c Renal Transplant Program   (United States)

Author keywords

Anti HLA antibody; Antibody mediated rejection; IVIG

Indexed keywords

COMPLEMENT COMPONENT C4D; HLA ANTIBODY; HLA ANTIBODY CLASS 1; HLA ANTIBODY CLASS 2; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; ADOLESCENT; ANTIBODY MEDIATED REJECTION; ANTIBODY RESPONSE; B LYMPHOCYTE; CHILD; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; LYMPHOCYTE ACTIVATION; PROGNOSIS; REVIEW; SENSITIZATION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODY SPECIFICITY; B-LYMPHOCYTES; CLINICAL PROTOCOLS; COMPLEMENT C3; CYTOTOXICITY TESTS, IMMUNOLOGIC; DESENSITIZATION, IMMUNOLOGIC; DOWN-REGULATION; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 16444372792     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00256.x     Document Type: Review

References (32)

1. COLVIN RB. Renal transplant pathology. In: JENNETTE JC, OLSON JL, SCHWARTZ MM, SILVA FG, eds. Heptinstall's Pathology of the Kidney. New York: Lippincott-Raven, 1998: pp. 1409-1540.
2. MAUIYYEDI S, CRESPO M, COLLINS AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologicclassification. J Am Soc Nephrol 2002: 13: 779-787.
3. BOHMIG GA, EXNER M, HABICHT A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002: 13: 1091-1099.
4. RACUSEN LC, COLVIN RB, SOLEZ K, et al. Antibody-mediated rejection criteria - an addition to the Banff'97 classification of renal allograft rejection. Am J Transplant 2003: 3: 708-714.
5. PATEL R, TERASAKI PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969: 280: 735-739.
6. LEE PC, TERASAKI PI, TAKEMOTO SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002: 74: 1192-1194.
7. MONTGOMERY RA, ZACHARY AA, RACUSEN LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887-895.
8. SCHWEITZER EJ, WILSON JS, FERNANDEZ-VINA M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000: 70: 1531-1536.
9. TYAN DB, LI VA, CZER L, TRENTO A, JORDAN SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994: 57: 553-562.
10. JORDAN SC, CUNNINGHAM-RUNDLES C, McEwAN R. Utility of IVIG in kidney transplantation. Am J Transplant 2003: 3: 653-664.
11. KAZATCHKINE MD, KAVERI SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001: 345: 747-755.
12. JORDAN SC, TYAN DB. Intravenous gamma globulin(IVIG) inhibits lymphocytotoxic antibody in vitro. J Am Society Nephrol 1991: 2: 803.
13. YADIN O, SEKIYA N. ETTENGER R. Intravenous immunoglobulin (IVIg) reduces antibody responses in highly sensitized dialysis patients. J Am Society Nephrol 1992: 3: 887.
14. GLOTZ D, HAYMANN JP, NIAUDET P, LANG P, DRUET P, BARIETY J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc 1995: 27: 1038-1039.
15. GLOTZ D, ANTOINE C, JULIA P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transplant Int 2004: 17: 1-8.
16. McINTYRE JA, HIGGINS N, BRITTON R. et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation 1996: 62: 691-693.
17. DE MARCO T, DAMON LE, COLOMBE B, KEITH F. CHATTERJEE K, GAROVOY MR. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 1997: 16: 360-365.
18. JORDAN SC, QUARTEL AW, CZER LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998: 66: 800-805.
19. CASADEI DH, DEL CRM, OPELZ G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001: 71: 53-58.
20. LUKE PP, SCANTLEBURY VP, JORDAN ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001: 72: 419-422.
21. BLASCZYK R, WESTHOFF U, GROSSE-WILDE H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993: 341: 789-790.
22. JORDAN SC, VO A, BUNNAPRADIST S. et al. Intravenous gammaglobulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003: 76: 631-636.
23. JORDAN SC, TYAN D, STABLEIN D, MCINTOSH M, VO A. Evaluation of IVIG as an agent to lower allosensitization and improve transplantation in highly-sensitized adult patients: Report of the NIH IG02 trial.(abstract). Am J Transplant 2003: 3: 551.
24. TOYODA M, ZHANG X, PETROSIAN A, GALERA OA, WANG SJ, JORDAN SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994: 14: 178-189.
25. MARCHALONIS JJ, KAYMAZ H, DEDEOGLU F, SCHLUTER SF, YOCUM DE. EDMUNDSON AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992: 89: 3325-3329.
26. SAMUELSSON A, TOWERS TL, RAVETCH JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001: 291: 484-486.
27. HUREZ V, KAVERI SV, MOUHOUB A, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994: 1: 269-277.
28. MAGEE JC, COLLINS BH, HARLAND RC, et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995: 96: 2404-2412.
29. SEMPLE JW, KIM M, LAZARUS AH, FREEDMAN J. Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. Blood 2002: 100: 1055-1059.
30. TOYODA M, PAO A, PETROSIAN A, JORDAN SC. Pooled human immune globulin (IVIG) modulates surface molecule expression and induces apoptosis in human B-cells. Am J Transplant 2003: 3: 156-166.
31. MAUIYYEDI S, DELLA P, SAIDMAN S, et al. C4d deposits in peritubular capillaries (PTC) in chronic renal allograft rejection (CR). Lab Invest 1999: 79: 156.
32. ONITSUKA S, YAMAGUCHI Y, TANABE K, TAKAHASHI K, TOMA H. Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transplantation with humoral rejection. Clin Transplant 1999: 13(Suppl. 1): 33-37.